Blog
RSS FeedPosted by Michael Wonder on 20 Feb 2023
Medicare annual statistics – rolling 12 months (July 2009 to December 2022)
20 February 2023 - This document presents rolling 12 month Medicare statistics by three variables ...
Posted by Michael Wonder on 08 Feb 2023
Stakeholders want more clarity on FDA's statistical approach to assessing bioequivalence
7 February 2023 - Commenters on the US FDA draft guidance outlining principles for in vivo or in vitro bioequivalence ...
Posted by Michael Wonder on 04 Dec 2022
Statistical approaches to establishing bioequivalence
2 December 2022 - Requirements for submitting bioavailability and bioequivalence data in investigational new drugs, new drug applications, abbreviated new drug ...
Posted by Michael Wonder on 31 Aug 2022
Pharmaceutical Benefits Scheme supplied medications
30 August 2022 - Key findings about health and population characteristics from the National Health Survey (NHS) and the Pharmaceutical Benefits ...
Posted by Michael Wonder on 04 Aug 2022
Regression models for ordinal outcomes
4 August 2022 - Ordinal logistic regression models are tailored for the analysis of ordinal outcomes. ...
Posted by Michael Wonder on 02 Aug 2022
Patient reported outcome measures in clinical research
2 August 2022 - Health conditions may cause patients to feel ill and have impaired functioning in their daily lives. Thus, ...
Posted by Michael Wonder on 07 Jul 2022
Testing for differences in survival when treatment effects are persistent, decaying, or delayed
7 July 2022 - A statistical test for the presence of treatment effects on survival will be based on a null ...
Posted by Michael Wonder on 23 Mar 2022
Instrumental variables and heterogeneous treatment effects
22 March 2022 - A randomised clinical trial can be used to estimate the average treatment effect for a population. ...
Posted by Michael Wonder on 15 Mar 2022
Collider bias
14 March 2022 - Bias is a systematic, non-random error in the estimation of a treatment effect or the effect of ...
Posted by Michael Wonder on 02 Mar 2022
Assessing unexpected circumstances that lead to modifications in clinical trial design, conduct, or analysis application of the CONSERVE Reporting Guideline
1 March 2022 - In the COVID-19 Dexamethasone (CoDEX) randomised clinical trial, which studied a sample of critically ill patients with ...
Posted by Michael Wonder on 14 Dec 2021
Heterogeneity of treatment effect; estimating how the effects of interventions vary across individuals
14 December 2021 - ...
Posted by Michael Wonder on 23 Nov 2021
Use of confidence intervals in interpreting non-statistically significant results
23 November 2021 - The goal of much of medical research is to determine which of 2 or more therapeutic approaches ...
Posted by Michael Wonder on 23 Aug 2021
Estimands, estimators and estimates
23 August 2021 - The primary goal of most randomised clinical trials is to draw conclusions about the effect of a ...
Posted by Michael Wonder on 17 Feb 2021
Immortal time bias in observational studies
16 February 2021 - Observational studies are commonly used to evaluate the association between a risk factor or “exposure” and the ...
Posted by Michael Wonder on 14 Feb 2021
Why proper understanding of confidence intervals and statistical significance is important
15 February 2021 - Guidelines for reporting results from randomised trials have long underscored the importance of confidence intervals. ...